California Supreme Court Rules In Favor Of Glaxo, FDA On Prop 65 Warnings
This article was originally published in The Tan Sheet
Executive Summary
State regulations that conflict with FDA requirements for drug labeling are preempted by federal law, the California Supreme Court ruled April 15 in a case involving Prop 65 warnings for OTC nicotine replacement therapies (NRT)